{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:33:34Z","timestamp":1781825614577,"version":"3.54.5"},"reference-count":20,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T00:00:00Z","timestamp":1537056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors have been shown to lower atherogenic lipid markers in patients with statin intolerance; however, external validity of these findings is unclear in patients with self-reported statin intolerance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of this study was to describe the tolerability of evolocumab and alirocumab in patients with self-reported statin intolerance. Secondary objectives were to describe their efficacy and obtainability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective chart review was completed and included adult patients with self-reported statin intolerance who were prescribed a PCSK9 inhibitor. Patient-reported side effects, laboratory values, and insurance information were collected for assessment of study objectives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>During the study period, 55 patients were prescribed PCSK9 inhibitor, 42 started therapy, and 34 had at least 1 follow-up visit. While myalgias occurred in 14.7% (n = 5) of patients, flu-like symptoms in 11.8% (n = 4), and fatigue in 2.9% (n = 1), only 5.9% (n = 2) of prescriptions for PCSK9 inhibitors were discontinued. Low-density lipoprotein cholesterol (LDL-C) was reduced 48.7% (95% confidence interval [CI]: -1.7%-99.1%), and 20 (58.8%) patients achieved a \u226550% reduction in LDL-C. Regarding obtainability, of the 57 prescriptions written, 77.2% (n = 44) required prior authorization and 5.3% (n = 3) were denied by insurance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>PCSK9 inhibitors were well tolerated in patients with self-reported statin intolerance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0897190018799218","type":"journal-article","created":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T00:51:40Z","timestamp":1537145500000},"page":"276-282","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Tolerance of Proprotein Convertase Subtilisin\/Kexin type 9 (PCSK9) Inhibitors in Patients With Self-Reported Statin Intolerance"],"prefix":"10.1177","volume":"33","author":[{"given":"Erica R.","family":"Davidson","sequence":"first","affiliation":[{"name":"The Ohio State University Wexner Medical Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Snider","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Bartsch","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Hirsch","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junan","family":"Li","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Larry","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,9,16]]},"reference":[{"key":"bibr1-0897190018799218","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv043"},{"key":"bibr2-0897190018799218","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"bibr3-0897190018799218","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2012.03.003"},{"key":"bibr4-0897190018799218","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.3670"},{"key":"bibr5-0897190018799218","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.519"},{"key":"bibr6-0897190018799218","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.02.003"},{"key":"bibr7-0897190018799218","unstructured":"Praluent [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2015."},{"key":"bibr8-0897190018799218","unstructured":"Repatha [package insert]. Thousand Oaks, CA: Amgen, Inc; 2015."},{"key":"bibr9-0897190018799218","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.08.006"},{"key":"bibr10-0897190018799218","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.3608"},{"key":"bibr11-0897190018799218","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"bibr12-0897190018799218","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.11004"},{"issue":"4","key":"bibr13-0897190018799218","first-page":"7","volume":"14","author":"Wojcik C","year":"2016","journal-title":"LipidSpin"},{"key":"bibr14-0897190018799218","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437738.63853.7a"},{"key":"bibr15-0897190018799218","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2011.04.003"},{"key":"bibr16-0897190018799218","volume-title":"Clinical Guidelines and Evidence Review for Familial Hypercholesterolaemia: The Identification and Management of Adults and Children with Familial Hypercholesterolaemia","author":"DeMott K","year":"2008"},{"key":"bibr17-0897190018799218","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.303.6807.893"},{"key":"bibr18-0897190018799218","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013189"},{"key":"bibr19-0897190018799218","unstructured":"Alirocumab. In: Lexi-Drugs Online. Hudson, OH: Lexi-Comp, Inc. http:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/5750788. Updated September 4, 2018; Accessed May 16, 2017."},{"key":"bibr20-0897190018799218","unstructured":"Evolocumab. In: Lexi-Drugs Online. Hudson, OH: Lexi-Comp, Inc. http:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/5764394. Updated July 24, 2018; Accessed May 16, 2017."}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190018799218","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190018799218","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190018799218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:35:11Z","timestamp":1777509311000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190018799218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,16]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1177\/0897190018799218"],"URL":"https:\/\/doi.org\/10.1177\/0897190018799218","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,16]]}}}